Summary
Global Markets Direct’s, ‘Pheochromocytoma - Pipeline Review, H1 2016’, provides an overview of the Pheochromocytoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pheochromocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pheochromocytoma
- The report reviews pipeline therapeutics for Pheochromocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pheochromocytoma therapeutics and enlists all their major and minor projects
- The report assesses Pheochromocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pheochromocytoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pheochromocytoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pheochromocytoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Exelixis, Inc.
MediaPharma s.r.l.
Pfizer Inc.
Progenics Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pheochromocytoma Overview 6
Therapeutics Development 7
Pipeline Products for Pheochromocytoma - Overview 7
Pipeline Products for Pheochromocytoma - Comparative Analysis 8
Pheochromocytoma - Therapeutics under Development by Companies 9
Pheochromocytoma - Therapeutics under Investigation by Universities/Institutes 10
Pheochromocytoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Pheochromocytoma - Products under Development by Companies 13
Pheochromocytoma - Products under Investigation by Universities/Institutes 14
Pheochromocytoma - Companies Involved in Therapeutics Development 15
Exelixis, Inc. 15
MediaPharma s.r.l. 16
Pfizer Inc. 17
Progenics Pharmaceuticals, Inc. 18
Valeant Pharmaceuticals International, Inc. 19
Pheochromocytoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
cabozantinib s-malate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
iobenguane sulfate I 131 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
metyrosine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MPHE-001B - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
S-43126 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
sunitinib malate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Pheochromocytoma - Recent Pipeline Updates 44
Pheochromocytoma - Dormant Projects 61
Pheochromocytoma - Product Development Milestones 62
Featured News & Press Releases 62
Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra 62
Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015 62
Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma 63
Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015 63
Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma 63
Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma 64
Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications 65
Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas 65
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68
List of Tables
Number of Products under Development for Pheochromocytoma, H1 2016 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Pheochromocytoma - Pipeline by Exelixis, Inc., H1 2016 15
Pheochromocytoma - Pipeline by MediaPharma s.r.l., H1 2016 16
Pheochromocytoma - Pipeline by Pfizer Inc., H1 2016 17
Pheochromocytoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 18
Pheochromocytoma - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 27
Pheochromocytoma Therapeutics - Recent Pipeline Updates, H1 2016 44
Pheochromocytoma - Dormant Projects, H1 2016 61
List of Figures
Number of Products under Development for Pheochromocytoma, H1 2016 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Top 10 Targets, H1 2016 21
Number of Products by Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 27
